Switch to
More onapp

How to use scorecard? Learn more

Mankind Pharma Ltd

MANKIND
Health CarePharmaceuticals
LargecapWith a market cap of ₹93,635 cr, stock is ranked 86
High RiskStock is 3.40x as volatile as Nifty
2,337.4558.20 (-2.43%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
LargecapWith a market cap of ₹93,635 cr, stock is ranked 86
High RiskStock is 3.40x as volatile as Nifty

Key MetricsEdit

No LabelNo Label
54.22
PB RatioPB Ratio
12.28
Dividend YieldDiv. Yield
Sector PESector PE
51.18
Sector PBSector PB
5.82
Sector Div YldSctr Div Yld
0.57%

Forecast & RatingsDetailed Forecast 

58%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Pro Only

Earnings

Earnings Growth

Pro Only

Revenue

Rev. Growth

Pro Only

See Detailed Forecast

Company Profile

Mankind Pharma Limited is an India-based pharmaceutical company. The Company is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It has a portfolio of formulations in several therapeutic areas, such as anti-infectives, cardiovascular, gastrointestinal, vitamins/minerals/nutrients, respiratory, anti-diabetic, dermatology, gynecology, and pain/analgesics, among others. Its other therapeutic areas include urology, ophthalmology, antiparasitic, stomatological, antineoplastic/immunomodulator, hepatoprotective, anti-malarial, blood-related, hormones, antiviral, sex stimulants/rejuvenators, anti-tuberculosis, parenteral and vaccines. Its portfolio of brands includes Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, and others.

Investor PresentationView older 

Aug 2, 2023

PDF
View Older Presentations

Financial TrendFinancial statements 

20202021202220235.996.407.998.891.031.271.431.28
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Decreased Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has decreased by 1.62%

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Increased Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has increased by 1.01%

See detailed holdings

Recent NewsAll news 

Hmm, looks like data is unavailable here. Please come back after some time
See all news

Recent EventsAll events 

Acquisition-XBRL 
Announced OnApr 2, 2024

Mankind Pharma Limited has informed the Exchange regarding Acquisition | Download

Mankind Pharma Limited has informed the Exchange regarding Acquisition | Download

Slump Sale-XBRL 
Announced OnApr 2, 2024

Mankind Pharma Limited has informed the Exchange regarding Slump Sale | Download

Mankind Pharma Limited has informed the Exchange regarding Slump Sale | Download

Acquisition 
Announced OnApr 2, 2024

The Board of Directors of the Company at its meeting held today i.e. April 2, 2024, has inter-alia,considered and approved the following:2. Incorporation of a wholly owned subsidiary by the name Mankind Consumer Products PrivateLimited or any other name approved by Registrar of Companies, Ministry of Corporate Affairs. | Download

The Board of Directors of the Company at its meeting held today i.e. April 2, 2024, has inter-alia,considered and approved the following:2. Incorporation of a wholly owned subsidiary by the name Mankind Consumer Products PrivateLimited or any other name approved by Registrar of Companies, Ministry of Corporate Affairs. | Download

See all events